Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September
29 août 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results
07 août 2018 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501
06 août 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
31 juil. 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer
16 juil. 2018 16h25 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
30 mai 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel
29 mai 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
17 mai 2018 09h20 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
15 mai 2018 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
08 mai 2018 16h01 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...